
Login
Who's Online
We have 495 guests and no members online
Statistics
- Users 5570
- Articles 752
- Articles View Hits 17732793
Why Use This Site for Advertisement?
Thank you for your interest in advertising on Gene Therapy Net. The website is active since January 2008 and the site's traffic grows day by day (see statistics). The visitors of Gene Therapy Net are professionals, doctors and researchers, as well as students, patients, regulatory affairs officers, government policy officers, and everyone else interested in gene therapy. |
|
Gene Therapy Net is run by a policy officer in the clinical gene therapy trial assessment procedure in the Netherlands. He has a scientific background in molecular biology and immunology. The website is a non-governmental, personal initiative and is aimed to provide comprehensive and accurate information about gene therapy, clinical trials, research news, and relevant gene therapy regulation and legislation. |
Advertisement Opportunities
Full banners, cube banners and text ads will be placed on highly visible sections throughout the site. Cube banners and text ads are placed in the left columns of the site, whereas full banners are placed in the middle wide column of the site. Your banner or text ad will be hyperlinked to the web address of your choice.
There are four different types of campaigns:
1 | Full banner | Located in rotation with other banners on all pages, including the home page |
2 | Home page banner or text links | Located only on the home page. Always visible in 1st or 2nd news item in center of the home page |
3 | Cube banner | Located on left ‘related links’ column on a minimum of 50% of all pages, including the home page |
4 | Text links | Located on left ‘related links’ column on a minimum of 50% of all pages, including the home page |
Advertisement Rates
We suggest a minimum of 3 months or at least 10,000 impressions, but please keep in mind that these rates and time lengths are not set in stone, but rather displayed to give you an idea on how our ad pricing is usually structured. By advertising on Gene Therapy Net, you agree to our terms and conditions listed below.
Contact us for more information about advertising.
Advertising Terms and Conditions: All ads are reviewed for correct usage, and must be approved prior to publication. Gene Therapy Net reserves the right to refuse advertising privileges to any web site for any reason, including the promotion of pornographic products and/or content, the advocating of illegal activities, immoral conduct, plagiarism, cheating, etc. Gene Therapy Net shall not be held responsible for grammatical errors, typographical errors, or errors in artwork provided by the advertiser. All ads are at the discretion of Gene Therapy Net. All rates are agreed on before advertisement is placed. Your ad will be place after full payment has been received. When an order has been received and payment taken for the service there will be no refund to the advertiser. Gene Therapy Net reserves the right to modify, change or otherwise improve upon the design and format of any or all of its pages at any time without notice. Gene Therapy Net reserves the right to modify, eradicate and/or change any or all of these terms and conditions without notice, including the right to change the above rates or to terminate this advertising program. We appreciate, but do not require, reciprocal links to Gene Therapy Net to be posted on your site.
Suggestions
Gene Therapy News
- Genflow advances gene therapy pipeline with new partnerships and patent progress - Proactive Investors
Tue, 17 Jun 2025 09:00:0 GMT - Europe's Only Public Longevity Company Advances 5 Gene Therapy Programs with Breakthrough SIRT6 Technology - Stock Titan
Tue, 17 Jun 2025 08:00:0 GMT - Gene Therapy Trial Shows Potential to Alter Progression of Duchenne Muscular Dystrophy - geneonline.com
Tue, 17 Jun 2025 07:51:5 GMT - Biotech pauses trial after second patient death linked to gene therapy - The Washington Post
Tue, 17 Jun 2025 06:20:5 GMT - BIO Notebook: IPO Window Stays Shut, PRVs Need To Be A Priority, And Focusing On Gene Therapy Safety - insights.citeline.com
Tue, 17 Jun 2025 03:06:4 GMT - Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - openPR.com
Tue, 17 Jun 2025 01:22:0 GMT - Mizuho's Jared Holz on what is next for Sarepta after second death connected to gene therapy - CNBC
Tue, 17 Jun 2025 00:00:0 GMT - Sarepta shares crash as second patient dies after receiving its gene therapy - MSN
Mon, 16 Jun 2025 23:42:0 GMT - Second Patient Dies After Gene Therapy for Duchenne Muscular Dystrophy - MedPage Today
Mon, 16 Jun 2025 22:46:5 GMT - Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio cream - Boston Herald
Mon, 16 Jun 2025 22:37:2 GMT - Sarepta Therapeutics Stock Drops 44.4% Amid Elevidys Gene Therapy Concerns - News and Statistics - IndexBox
Mon, 16 Jun 2025 22:25:4 GMT - Gene Therapy Experts Discuss Regulatory and Financial Challenges at FDA Forum - geneonline.com
Mon, 16 Jun 2025 22:06:5 GMT - Second patient death reported with gene therapy for muscular dystrophy - El Paso Inc.
Mon, 16 Jun 2025 22:05:2 GMT - Second patient death reported with gene therapy for muscular dystrophy - Ottumwa Courier
Mon, 16 Jun 2025 22:05:2 GMT - Second patient death reported with gene therapy for muscular dystrophy - Imperial Valley Press Online
Mon, 16 Jun 2025 22:05:2 GMT